<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 02 Mar 2021 08:01:18 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>小药谈ICI：TIGIT</title><link>https://mp.weixin.qq.com/s/FMUf4SN1s4h3qoBaMTmjmw</link><description></description><content:encoded><![CDATA[小药谈ICI：TIGIT]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：lAG-3</title><link>https://mp.weixin.qq.com/s/khkOmFLQbjTU_bYDmGzD6A</link><description></description><content:encoded><![CDATA[小药谈ICI：lAG-3]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：TIMs，TAMs和PS</title><link>https://mp.weixin.qq.com/s/E3YULQbIuGuiSFAnsb-Sxw</link><description></description><content:encoded><![CDATA[小药谈ICI：TIMs，TAMs和PS]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：VISTA</title><link>https://mp.weixin.qq.com/s/FbhQjT6RoyT-5FXmsKNelQ</link><description></description><content:encoded><![CDATA[小药谈ICI：VISTA]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：B7-H3</title><link>https://mp.weixin.qq.com/s/cMxZv1s2iFHgOsidC_rbAA</link><description></description><content:encoded><![CDATA[小药谈ICI：B7-H3]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：CD47</title><link>https://mp.weixin.qq.com/s/l83RplruaMBwDQSh5p-FmQ</link><description></description><content:encoded><![CDATA[小药谈ICI：CD47]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：突破还是延续？</title><link>https://mp.weixin.qq.com/s/otrpNHNOZ4T4aAiozQDfVA</link><description></description><content:encoded><![CDATA[小药谈ICI：突破还是延续？]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈ICI：临床挑战</title><link>https://mp.weixin.qq.com/s/hJSKlvwQZnnhBSigSs7Zsg</link><description></description><content:encoded><![CDATA[小药谈ICI：临床挑战]]></content:encoded><pubDate>Tue, 02 Mar 2021 06:30:29 +0800</pubDate></item><item><title>小药谈TNFRSF之CD40</title><link>https://mp.weixin.qq.com/s/oYgi8slR7uzK20JKGQWh9g</link><description></description><content:encoded><![CDATA[小药谈TNFRSF之CD40]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈TNFRSF之OX40</title><link>https://mp.weixin.qq.com/s/LG7d8FMu8sd4dg3EwmWzZg</link><description></description><content:encoded><![CDATA[小药谈TNFRSF之OX40]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈TNFRSF之4-1BB</title><link>https://mp.weixin.qq.com/s/-jTt3Q3NBJfLc_3zM7_8MA</link><description></description><content:encoded><![CDATA[小药谈TNFRSF之4-1BB]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈TNFRSF之GITR</title><link>https://mp.weixin.qq.com/s/STejSiZx0z9QAdCztEELTw</link><description></description><content:encoded><![CDATA[小药谈TNFRSF之GITR]]></content:encoded><pubDate>Mon, 01 Mar 2021 06:06:37 +0800</pubDate></item><item><title>小药谈GPCR: GPCR抗体药物的研发进展</title><link>https://mp.weixin.qq.com/s/ahyNPrVk0UTzZmBvT8IhGA</link><description></description><content:encoded><![CDATA[小药谈GPCR: GPCR抗体药物的研发进展]]></content:encoded><pubDate>Sun, 28 Feb 2021 06:24:26 +0800</pubDate></item><item><title>小药谈GPCR: GPCR药物开发现状及发展趋势</title><link>https://mp.weixin.qq.com/s/PAy1veg3Y8J2SSboGLWN6w</link><description></description><content:encoded><![CDATA[小药谈GPCR: GPCR药物开发现状及发展趋势]]></content:encoded><pubDate>Sun, 28 Feb 2021 06:24:26 +0800</pubDate></item><item><title>小药谈GPCR: GPCR药物靶点的自然遗传变异</title><link>https://mp.weixin.qq.com/s/-C-NVBDKmtDmQsF29nwdFQ</link><description></description><content:encoded><![CDATA[小药谈GPCR: GPCR药物靶点的自然遗传变异]]></content:encoded><pubDate>Sun, 28 Feb 2021 06:24:26 +0800</pubDate></item><item><title>小药谈GPCR: GPCR的偏向配体</title><link>https://mp.weixin.qq.com/s/zWRwBzAQ6IzJtRPfZN42iw</link><description></description><content:encoded><![CDATA[小药谈GPCR: GPCR的偏向配体]]></content:encoded><pubDate>Sun, 28 Feb 2021 06:24:26 +0800</pubDate></item><item><title>4-1BB+T细胞：免疫治疗革命的主角</title><link>https://mp.weixin.qq.com/s/55QEhwhhgrRJe3b8b83drw</link><description></description><content:encoded><![CDATA[4-1BB+T细胞：免疫治疗革命的主角]]></content:encoded><pubDate>Sat, 27 Feb 2021 06:58:23 +0800</pubDate></item><item><title>药物发现中的人工智能：关于物理数据和生物数据的讨论</title><link>https://mp.weixin.qq.com/s/reqCBovjJnyOHmKlHo2Now</link><description></description><content:encoded><![CDATA[药物发现中的人工智能：关于物理数据和生物数据的讨论]]></content:encoded><pubDate>Thu, 25 Feb 2021 06:35:45 +0800</pubDate></item><item><title>抗Galectin-9与GITR激动剂的协同抗肿瘤作用</title><link>https://mp.weixin.qq.com/s/S0k5-II4uueuFJm-6h-Izw</link><description></description><content:encoded><![CDATA[抗Galectin-9与GITR激动剂的协同抗肿瘤作用]]></content:encoded><pubDate>Tue, 23 Feb 2021 06:54:37 +0800</pubDate></item><item><title>自身免疫与炎症性疾病生物疗法三十年来的经验总结</title><link>https://mp.weixin.qq.com/s/oKAgcPYP4-ZNPdv4x80Bhg</link><description></description><content:encoded><![CDATA[自身免疫与炎症性疾病生物疗法三十年来的经验总结]]></content:encoded><pubDate>Sun, 21 Feb 2021 06:55:19 +0800</pubDate></item></channel></rss>